Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01309022|
Expanded Access Status : No longer available
First Posted : March 4, 2011
Last Update Posted : February 9, 2016
|First Submitted Date||March 2, 2011|
|First Posted Date||March 4, 2011|
|Last Update Posted Date||February 9, 2016|
|Brief Title||Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)|
|Brief Summary||The purpose of this protocol is to provide continued acess to immunosuppressive medications to subjects from the completed/closed trial ITN005CT (NIS01,NCT00014911). THIS PROTOCOL DOES NOT PROVIDE MEDICINES TO DIABETES PATIENTS WHO DID NOT PARTICIPATE IN ITN005CT.|
Study acronym: EXIIST - Extended Immunosuppression in Islet Transplantation
Islet transplantation is an experimental therapy in people with difficult to control Type 1 diabetes (T1D). Insulin producing cells (islets) are isolated from a pancreas. After the cells are prepared, the islets are put into the subject's liver. These transplanted islets may produce insulin that the subject's islets can no longer make. In order to help keep up the function of the transplanted islets, immunosuppressive medications must be given indefinitely or for as long as the study doctor determines is necessary. The medications serve to modify the immune system that normally tries to destroy (reject) new islets.
Participants in this study have received up to three islet cell infusions as a previous participant in the ITN005CT (NIS01) protocol. They also received a maintenance immunosuppressive treatment regimen consisting of a combination of orally administered drugs (tacrolimus (Prograf®), sirolimus (Rapamune®), mycophenolate mofetil (MMF, Cellcept®), and/or mycophenolic acid (MPA, Myfortic®).) This protocol provides a way to supply these immunosuppressive medications to subjects whose islets continue to function and make C-peptide.
Routine study follow-up visits will occur on an annual and -as warranted basis.
|Study Type||Expanded Access|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Expanded Access Status||No longer available|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||United States|
|Removed Location Countries|
|Responsible Party||National Institute of Allergy and Infectious Diseases (NIAID)|
|Study Sponsor||National Institute of Allergy and Infectious Diseases (NIAID)|
|Collaborators||Immune Tolerance Network (ITN)|
|PRS Account||National Institute of Allergy and Infectious Diseases (NIAID)|
|Verification Date||February 2016|